Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart spacer could help kids breathe easier

NCT ID NCT07500246

Disease control Sponsor: Luxembourg Institute of Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new digital spacer (Whizz) helps children aged 5-16 with asthma use their inhaler correctly and stick to their medication, compared to a standard spacer. Researchers will also look for biomarkers in blood and breath to improve diagnosis and understand how environment affects asthma. The goal is to improve asthma control and quality of life for kids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inhaled corticosteroids (via spacer device)
What this could lead to
If successful, this could show that a digital spacer helps children use their inhaler correctly and stick to their medication, leading to better asthma control.
What could go wrong
This is a relatively small, early-stage trial focused on device usability and adherence, not a new drug. Results may not apply to all children or guarantee long-term improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 208 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged between 5-16 years, male or female * Physician diagnosis of asthma requiring a controller treatment with ICS or ICS/Long-acting beta-agonists (LABA) via MDI * Partly controlled or uncontrolled asthma based on GINA criteria and definitions * Informed consent signed by legally authorized representatives (LAR) and assent from young patient (only applicable for children ≥ 10 years) Exclusion Criteria: * Patients with severe asthma exacerbation treated with systemic corticosteroids within the last 2 weeks or patients with active respiratory tract infection * Diagnosis of underlying chronic lung disease other than asthma (e.g., BPCO/cystic fibrosis etc.) * Severe asthma based on GINA definitions * Severe underlying disorders ((severe congenital heart disease, oncologic patients) (non-exhaustive list, left to the evaluation of the PI)) * Immune deficiency or under immunosuppressive treatments * In receipt of immunotherapy (only for participants in Luxembourg donating samples for biomarker research) * Patients with neurological diseases / impaired cognitive disorder * Siblings of patients already included in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease asthma childhood onset asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Asthma childhood Inhalation spacers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Luxembourg Research Clinic (LRC)

    RECRUITING

    Luxembourg, Luxembourg

More trials for these conditions

Other studies related to the condition(s) this trial covers.